Who is sponsoring NCT05368350?

NCT05368350 is sponsored by The University of Texas at Dallas.

What drugs are being tested in NCT05368350?

Interventions in NCT05368350: high-definition transcranial direct current stimulation (HD-tDCS).

What condition does NCT05368350 study?

NCT05368350 studies Primary Progressive Aphasia, Apraxia of Speech.

Is NCT05368350 still recruiting?

NCT05368350 is currently active, enrolled. Last updated 4 May 2025.

Last reviewed 2025-05-04 · How we verify

NCT05368350

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation

Active, enrolled NA Last updated 4 May 2025

What this trial tests

NA trial testing high-definition transcranial direct current stimulation (HD-tDCS) in Primary Progressive Aphasia in 12 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 June 2022

Primary endpoint
16 April 2026

16 April 2026

Quick facts

Lead sponsor	The University of Texas at Dallas
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 June 2022
Primary completion	16 April 2026
Estimated completion	16 April 2026
Sites	1 location across United States

Drugs / interventions tested

high-definition transcranial direct current stimulation (HD-tDCS)

Conditions studied

Primary Progressive Aphasia — all drugs for Primary Progressive Aphasia →
Apraxia of Speech — all drugs for Apraxia of Speech →

Sponsor

The University of Texas at Dallas

Who can join

Adults 18 to 85, any sex, with Primary Progressive Aphasia or Apraxia of Speech. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., pre-supplementary motor area and left inferior frontal gyrus) thought to aid in memory will improve speech and language difficulties in patients with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS). The primary outcome measures are neuropsychological assessments of speech and language functions, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Non-pharmacological interventions for improving language and communication in people with primary progressive aphasia.
Roheger M, Riemann S, Brauer A, McGowan E, et al · · 2024 · cited 13× · PMID 38808659 · DOI 10.1002/14651858.cd015067.pub2
High-definition brain stimulation targeting separate regions leads to differential word retrieval outcomes in patients with primary progressive aphasia: a pilot study.
Dugas CS, Chiang HS, Devora P, Lucas-Mendoza K, et al · · 2025 · PMID 41041680 · DOI 10.3389/fneur.2025.1630103

Verify or expand the search:

Other trials of high-definition transcranial direct current stimulation (HD-tDCS)

Trials testing the same drug.

NCT07063264 — Effects of HD-tDCS During Slow-wave Sleep on Associative Memory · NA · completed

Other recruiting trials for Primary Progressive Aphasia

Currently open trials in the same condition.

NCT06191198 — Communication Bridge 3 Study · Phase 2 · recruiting
NCT06211374 — Communication Bridge Pilot Study · NA · active not recruiting
NCT05386394 — Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia · Phase 2 · recruiting
NCT05741853 — Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia · NA · recruiting
NCT05443633 — Enhancing Language Function in Aphasia · NA · recruiting

Other The University of Texas at Dallas trials

Trials by the same sponsor.

NCT07534397 — Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current · NA · not yet recruiting
NCT07354139 — Using Non-invasive Brain Stimulation to Explore Potential Treatments to Reduce Speech Errors in Adults Who Stutter · NA · recruiting
NCT07206550 — The Role of Framing and Choice Architecture in Patients' Reactions and EHR Error Discovery and Reporting · NA · enrolling by invitation
NCT06731452 — Exploring Neurophysiological Markers of Brain Health · NA · recruiting
NCT06724887 — Brain Health on College Campuses · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05368350 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas at Dallas
Last refreshed: 4 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05368350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing